AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
cefaloridine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, cefalosporanic acid derivatives | 573 | 50-59-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A cephalosporin antibiotic.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 3 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 206.30 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
| Vd (Volume of distribution) | 0.46 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 3.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.80 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.50 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 20 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BA (Bioavailability) | 0 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -0.685 | High | 0.88 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 2.208 | High | 0.88 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 1.390 | 10^-6 cm/s | High | 0.88 |
| dh-clint | Dog hepatocyte intrinsic clearance | 3.177 | uL/min/10^6 cells | High | 0.88 |
| dppb | Dog plasma protein binding (% unbound) | 65.840 | % | High | 0.88 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 56.300 | % | High | 0.88 |
| herg | hERG pIC50 | 4.422 | pIC50 | High | 0.88 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.968 | uL/min/10^6 cells | High | 0.88 |
| hlm-clint | Human liver microsomal intrinsic clearance | 13.428 | uL/min/mg protein | High | 0.88 |
| hppb | Human plasma protein binding (% unbound) | 46.320 | % | High | 0.88 |
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TTK,ZAP70 | 46 | |||
| kinase-selectivity-class | AXL,GRK2,MAP2K6,MAPK7,STK33,TEK,TTK | 7 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 4.467 | High | 0.88 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 2.535 | High | 0.88 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 10.593 | High | 0.88 | |
| mppb | Mouse plasma protein binding (% unbound) | 55.730 | High | 0.88 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 5.420 | High | 0.88 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 61.200 | % | High | 0.88 |
| rat-kpuu-brain | Rat brain Kpuu | 0.010 | % | High | 0.88 |
| rh-clint | Rat hepatocyte intrinsic clearance | 7.907 | uL/min/10^6 cells | High | 0.88 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 85.650 | % | High | 0.88 |
| rppb | Rat plasma protein binding (% unbound) | 49.080 | % | High | 0.88 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 509.331 | uM | High | 0.88 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01DB02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS First-generation cephalosporins |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
Related Drugs by ATC class:
J01DB First-generation cephalosporins 11 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.83 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| N0000008008 | NUI |
| D01075 | KEGG_DRUG |
| 2233 | RXNORM |
| C0007727 | UMLSCUI |
| CHEBI:3537 | CHEBI |
| CHEMBL316157 | ChEMBL_ID |
| DB09008 | DRUGBANK_ID |
| 12189 | IUPHAR_LIGAND_ID |
| 5773 | PUBCHEM_CID |
| 002713 | NDDF |
| 28588009 | SNOMEDCT_US |
| 702746007 | SNOMEDCT_US |
| D002509 | MESH_DESCRIPTOR_UI |
| 1910 | INN_ID |
| LVZ1VC61HB | UNII |
| LVZ1VC61HB | INXIGHT DRUGS |
Pharmaceutical products:
None